Streetwise Expert Interviews

Scott Power

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. (4/17/14) More >


Read more Streetwise interviews. . .

including Don't Miss the Boat on Big Biotech Catalysts: Keith Markey (4/10/14) More >


Read more Streetwise interviews. . .

including Hang On, FolksŚIt's Going to Be a Bumpy Ride: 2014 Biotech Watchlist Update (4/10/14) More >

Newsletter Briefs

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey Moreá>

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum Moreá>

"ATHX's MultiStem has the potential to completely change existing treatment paradigms." (4/2/14) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"Our price target on DMPI represents 294% upside potential." (3/31/14) DelMar Pharmaceuticals Inc. - SeeThruEquity Moreá>

"We believe AMBS' MANF molecule is one of the jewels in the field." (3/26/14) Amarantus BioScience Holdings Inc. - The Life Sciences Report Interview with David Lowe Moreá>

"NBS increased its operating margin and lowered its production cost." (3/25/14) NeoStem Inc. - Shawn Arshad, Seeking Alpha Moreá>

"BLU presented to our advisory board and came out as one of the favorites." (3/19/14) BELLUS Health Inc. - The Life Sciences Report Interview with Hugh Cleland Moreá>

"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland Moreá>

Expert Analysis

"CYTX's corporate direction will not change with the new CEO." (4/3/14) Cytori Therapeutics Inc. - Yale Jen, Laidlaw & Company Moreá>

"We are initiating coverage on DMPI with a Buy rating." (4/2/14) DelMar Pharmaceuticals Inc. - Jason Kolbert, Maxim Group Moreá>

"OPK launched 4KScore in the U.S. as a test for prostate cancer." (4/1/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann Moreá>

"BFLS' offering opened at $4.30, down from $5.24; do the math, Buy!" (3/26/14) BioLife Solutions Inc. - Henry McCusker, Scimitar Equity LLC Moreá>

"Gross margins for CGIX's base business could double in 18ľ24 months." (3/27/14) Cancer Genetics Inc. - Raghuram Selvaraju, Aegis Capital Corp. Moreá>

"Our price target on DMPI represents 294% upside potential." (3/31/14) DelMar Pharmaceuticals Inc. - SeeThruEquity Moreá>

"Interim results showed increased blood concentration of CTH's drug." (3/31/14) Cynapsus Therapeutics Inc. - Jerry Isaacson, LifeSci Advisors Moreá>

"BFLS' contract manufacturing business is expected to provide a source of near-term revenue and cash flow." (3/31/14) BioLife Solutions Inc. - Brian Marckx, Zacks Investment Research Moreá>